
About Alfasigma
Alfasigma is a Healthcare company based in Bologna (Italy) founded in 2015. Generic tablets, capsules, syrups, and injectables are manufactured. Alfasigma has completed 4 acquisitions, including Intercept Pharmaceuticals, Jyseleca and Pamlab. Its chief executive, as recorded, is Bryan Downey. Its website alfasigma.com draws about 55 thousand monthly visits. Its Indian entity Alfasigma India Private Limited reported revenue of βΉ90 Lakh. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Alfasigma was established in 2015 and is based in Bologna, Italy, within the pharmaceutical sector. Finished generic formulations, including tablets, capsules, syrups, and injectables, are produced by the company. Operations focus on key products such as rifaximin, carnitine, sulodexide, and parnaparin, supporting generic drug distribution across various markets.
- Headquarters Bologna, Italy
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website alfasigma.com
- Social LinkedIn
- Legal Name Alfasigma India Private Limited
- Date of Incorporation 06 Aug, 2008
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹90 Lakh
FY 2022 · +4% YoY
- Indian entity net loss-₹31.6 Lakh
FY 2022 · -35% margin
- Latest Funding Round$176.07M (USD), Debt – Conventional
Jul 2025
- InvestorsBPER Banca
& 1 more
- Investments & AcquisitionsIntercept Pharmaceuticals
& 3 more
Associated legal entities of Alfasigma
Alfasigma operates through Alfasigma India Private Limited (under liquidation). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Alfasigma India Private Limited CIN U24231MH2008FTC185531 | Under Liquidation | 06 Aug 2008 | Mumbai, Maharashtra | ₹0.9 Cr | 4 | View details |
Funding Insights of Alfasigma
- Total Rounds 2
- Last Round Debt – Conventional β $176.07M
- First Round $169.66M
(May 2025)
- Investors Count 2
All 2 funding rounds of Alfasigma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $176.07M | Debt – Conventional | β | β | |
| May 2025 | $169.66M | Debt – Conventional | β | β |
2 investors in total: 2 institutional.
Investors in Alfasigma
Alfasigma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BPER Banca and European Investment Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Regional banking and investment services are provided to various clients. | 1867 | bper.it | Modena, Italy |
Investor details for Alfasigma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Alfasigma India Private Limited (Alfasigma)
Alfasigma India Private Limited is the primary company behind Alfasigma. The board of Alfasigma India Private Limited currently have 4 directors; the longest-serving is Stefano Pasi, appointed in 2016. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Stefano Pasi DIN 07470451 | Director | 15 Mar 2016 | 10 yrs 8 mo | Alfasigma India Private Limited |
| Giuseppe Allocca DIN 08909639 | Director | 08 Oct 2020 | 6 yrs 1 mo | Alfasigma India Private Limited |
| Kumar Krishnan Iyer DIN 00034834 | Director | 01 Mar 2023 | 3 yrs 8 mo | Alfasigma India Private Limited |
| Rakesh Maganlal Nathwani DIN 00141935 | IRP/RP/Liquidator | 18 Dec 2023 | 2 yrs 11 mo | Alfasigma India Private Limited |
People of Alfasigma
1 people are tracked at Alfasigma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Bryan Downey | CEO & President | Leadership |
Complete people profiles for Alfasigma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Alfasigma
Figures of Alfasigma India Private Limited, the primary company behind Alfasigma, for FY 2022. Revenue was ₹90 Lakh (+4% year on year). Net loss was -₹31.6 Lakh (-35% margin). Revenue has grown at a compounded annual rate of +12% over three years.
- ₹90 LakhRevenue · FY 2022 · +4% YoY
- -₹31.6 LakhNet loss · -35% margin
- ₹3.74 CrPaid-up capital
- +12%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Alfasigma India Private Limited are on its company page.
Detailed financial statements for Alfasigma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alfasigma
Alfasigma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Intercept Pharmaceuticals, Jyseleca and Pamlab.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drug information is provided through the Jyseleca website. | 0 | Feb 2024 | β’β’β’β’ | |||
Developer of therapeutics to treat progressive non-viral liver diseases | interceptpharma.com | New York, United States | 2002 | Sep 2023 | $794M | |
Pharmaceutical finished products such as tablets and capsules are manufactured. | sofarfarm.it | Trezzano Rosa, Italy | 1968 | Aug 2022 | β’β’β’β’ | |
Pharmaceutical company providing prescription medical food | pamlab.com | Covington, United States | 1957 | Jan 2017 | β’β’β’β’ |
Complete acquisition details for Alfasigma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alfasigma
7 dated milestones of Alfasigma across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Alfasigma is founded.
- Acquisition Acquires Pamlab.
- Acquisition Acquires Sofar.
- Acquisition Acquires Intercept Pharmaceuticals.
- Acquisition Acquires Jyseleca.
- Funding First funding round of $169.7M.
- Funding Latest funding round, Debt β Conventional, of $176.1M.
Web traffic of Alfasigma
The website of Alfasigma (alfasigma.com) receives about 55.2K visits a month and ranks #605,770 among all websites worldwide, #643 in Biotechnology and Pharmaceuticals.
- Monthly visits55.2K
▲ 12.1% vs previous month
- Unique visitors21.2K
per month
- Global rank#605,770
among all websites
- Category rank#643
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.5
- Average visit27 sec
- DevicesDesktop 44% Β· Mobile 56%
Websites whose visitors overlap most with Alfasigma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
clinvest.ru | clinvest.ru | 100% | #972,098 | β | |
| labworld.it | 96% | #1,872,223 | View details | ||
| acino.swiss | 96% | 8.5K | #2,030,551 | View details | |
| granfarmaciaonline.es | 72% | #1,534,599 | View details | ||
farmaciamarquesbraga.pt | farmaciamarquesbraga.pt | 72% | #4,269,161 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 32 similar websites and full traffic analytics for Alfasigma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 32 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Alfasigma
Alfasigma was founded in 2015 and raised its 1st funding round 10 years after it was founded.
Alfasigma is headquartered in Bologna, Italy. It is registered at Bologna, Emilia-romagna, Italy.
Bryan Downey is the CEO of Alfasigma, as recorded in our data.
The primary company behind Alfasigma, Alfasigma India Private Limited, reported revenue of βΉ90 Lakh for FY 2022, up 4% year on year.
Alfasigma was established in 2015 and is based in Bologna, Italy, within the pharmaceutical sector. Finished generic formulations, including tablets, capsules, syrups, and injectables, are produced by the company. Operations focus on key products such as rifaximin, carnitine, sulodexide, and parnaparin, supporting generic drug distribution across various markets.
Alfasigma has made 4 acquisitions, including Intercept Pharmaceuticals, Jyseleca, and Pamlab.
Alfasigma has 2 investors. Key investors include BPER Banca, and European Investment Bank.
Alfasigma operates through Alfasigma India Private Limited.
The legal entities of Alfasigma currently have 4 directors, including Giuseppe Allocca, Stefano Pasi, Kumar Krishnan Iyer and others.